Biotech · Private company
BioNumerik Pharmaceuticals, Inc.
Track this companyFree. Adds BioNumerik Pharmaceuticals, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials40 recruiting or active
Pipeline programs4From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline4
- Tavocept(BNP7787) in combination with cisplatin and either docetaxel or paclitaxelPhase 3 · Non-small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- Karenitecin (BNP1350)Phase 2 · Brain NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- Karenitecin (BNP1350)Phase 2 · MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- Karenitecin (BNP1350)Phase 1 · CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials4
- Phase 3 Study of Tavocept Versus Placebo in Patients With Newly Diagnosed or Relapsed Advanced Primary Adenocarcinoma of the Lung Treated With Docetaxel or Paclitaxel Plus CisplatinPHASE3 · COMPLETED · started Apr 1, 2010ClinicalTrials.gov NCT00966914 · fetched Nov 12, 2026
- Trial of Oral Karenitecin in Patients With Solid Tumors and Lung CancerPHASE1 · COMPLETED · started May 1, 2004ClinicalTrials.gov NCT00097903 · fetched Nov 12, 2026
- Study of Karenitecin (BNP1350) to Treat Malignant MelanomaPHASE2 · COMPLETED · started May 1, 2002ClinicalTrials.gov NCT00062491 · fetched Nov 12, 2026
- Study of Karenitecin (BNP1350) in Patients With Brain TumorsPHASE2 · COMPLETED · started Oct 1, 2001ClinicalTrials.gov NCT00062478 · fetched Nov 12, 2026